Celsion Corp. (CLSN) Starts Presentation at Biotech Showcase Conference

Celsion Corp. (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company’s lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in phase III development for the treatment of primary liver cancer and phase II development for the treatment of recurrent chest wall breast cancer. For more information, visit the company’s website at www.celsion.com.